Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Updated AI Software for CT-Based Coronary Artery Calcium Assessment
Key features of the HealthCCSng V2.0 software include numerical coronary artery calcium (CAC) scoring, a new zero CAC category and user customization of upper and lower limits for CAC scoring categories.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the HealthCCSng V2.0 software, which features updates to facilitate automated assessments of coronary artery calcium (CAC) scoring based on non-contrast computed tomography (CT) scans.
The HealthCCSng V2.0 software offers three new benefits, according to Nanox.AI, the developer of the software.
The company said a new Zero CAC category enables clinicians to more easily differentiate between patients with low CAC levels and those with zero CAC, which corresponds to a very low risk for cardiac events.
The updated HealthCCSng V2.0 software also allows more fine-tuning of coronary artery calcium (CAC) assessments with automated numerical CAC scoring and the ability to adjust the upper and lower Hounsfield unit bounds of CAC scoring categories, according to Nanox.AI. (Graphic courtesy of Nanox.)
The updated software also allows more fine-tuning of CAC assessments with automated numerical CAC scoring and the ability to adjust the upper and lower Hounsfield unit bounds of CAC scoring categories, according to Nanox.AI.
“The AI cardiac solution helps to bridge the divide between radiology and cardiology, two medical specialties that often use different terms and descriptions to assess imaging data and catches patients who might otherwise fall through the cracks so that they can be directed to appropriate preventative healthcare,” noted Erez Meltzer, the chief executive officer for Nanox.
Recent Videos
Related Content
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024Article
The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
